The deal has already been cleared in several countries, including the US, Japan, and China, and the firms are targeting a close in mid-2015.
The deal gives EMD Millipore control of Singulex's single-molecule counting technology for research applications.
Lucigen's CEO said the agreement will provide researchers in India with his firm's technologies for use with NGS, cloning, and protein expression systems.
On an organic basis, Sigma-Aldrich's revenue growth was 5 percent for the quarter, with double-digit organic sales growth in the Life Sciences Services segment.
Sigma-Aldrich will take over distribution of Roche's Biochemical Reagents product portfolio so Roche can focus on other areas of its business.
Sigma-Aldrich announced the acquisition of the provider of in vitro diagnostic antibody reagent and kits in October without disclosing the price.
The firm will provide reagents and consult on experimental designs with the Center's Institute of Molecular Genetics.
The deal needs regulatory approval in other countries but is still expected to be completed in mid-2015.
The shift back toward therapeutics marks a return to the company's initial focus, which it put on hold last year due to a challenging funding environment.
The collaboration will explore use of the PCC agents, which are synthetic peptides with functions similar to traditional antibodies, for protein research.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.